These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19892769)

  • 1. Comment on alemtuzumab and inclusion body myositis.
    Greenberg SA
    Brain; 2010 May; 133(Pt 5):e135; author reply e136. PubMed ID: 19892769
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.
    Dalakas MC; Rakocevic G; Schmidt J; Salajegheh M; McElroy B; Harris-Love MO; Shrader JA; Levy EW; Dambrosia J; Kampen RL; Bruno DA; Kirk AD
    Brain; 2009 Jun; 132(Pt 6):1536-44. PubMed ID: 19454532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Zent CS
    Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab in lymphoproliferate disorders.
    Dearden CE
    Rev Clin Exp Hematol; 2002 Dec; 6(4):435-48; discussion 449-50. PubMed ID: 12823782
    [No Abstract]   [Full Text] [Related]  

  • 5. A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab.
    Ioannis M; Foivos P; Dimitrios K
    Int J Neurosci; 2019 Mar; 129(3):297-302. PubMed ID: 30238817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
    Keating M; Hallek M
    Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
    Lee D
    Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
    Amengual JE; Raphael BG
    Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
    [No Abstract]   [Full Text] [Related]  

  • 9. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
    Smith JA
    Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
    Rosenblum MD; LaBelle JL; Chang CC; Margolis DA; Schauer DW; Vesole DH
    Blood; 2004 Mar; 103(5):1969-71. PubMed ID: 14976065
    [No Abstract]   [Full Text] [Related]  

  • 11. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome.
    Sefcick A; Sowter D; DasGupta E; Russell NH; Byrne JL
    Br J Haematol; 2004 Feb; 124(4):558-9. PubMed ID: 14984510
    [No Abstract]   [Full Text] [Related]  

  • 12. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 13. Prope tolerance with alemtuzumab.
    Calne RY
    Liver Transpl; 2005 Mar; 11(3):361-3. PubMed ID: 15719401
    [No Abstract]   [Full Text] [Related]  

  • 14. Alemtuzumab-resistant Sézary syndrome responding to zanolimumab.
    Alexandroff AB; Shpadaruk V; Bamford WM; Kennedy DB; Burd R; Dyer MJ
    Br J Haematol; 2011 Aug; 154(3):419-21. PubMed ID: 21480857
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab treatment for hemophagocytic lymphohistiocytosis.
    Machaczka M; Vaktnäs J; Chiang SC; Bryceson YT
    Nat Rev Clin Oncol; 2010 Oct; 7(10):. PubMed ID: 21080519
    [No Abstract]   [Full Text] [Related]  

  • 16. Campath-1H for chronic lymphocytic leukemia.
    Rai KR
    Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation.
    Sureshkumar KK; Hussain SM; Zimmer BW; Marcus RJ
    Expert Opin Biol Ther; 2008 Oct; 8(10):1605-25. PubMed ID: 18774927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
    Worth LJ; Thursky KA
    Leuk Lymphoma; 2006 Dec; 47(12):2435-6. PubMed ID: 17169785
    [No Abstract]   [Full Text] [Related]  

  • 19. Alemtuzumab in kidney-transplant recipients.
    Luan FL
    N Engl J Med; 2011 Aug; 365(7):671; author reply 671-2. PubMed ID: 21848469
    [No Abstract]   [Full Text] [Related]  

  • 20. [Alemtuzumab in early multiple sclerosis].
    Killestein J; Polman CH
    Ned Tijdschr Geneeskd; 2009 Jan; 153(1-2):46. PubMed ID: 19198214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.